Project Grant R01HL174525
Award Date
8/10/24
Completion Date
5/31/29
Dollars Obligated
$1.7M
Federal Agency
National Heart Lung and Blood Institute
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Durham, NC 27705, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $684,814 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF) to conduct research on the suppression of alveolar stem cells by tissue-resident lymphocytes in emphysema. The research aims to investigate how lung stromal factors modify the inflammatory response to viral infections and tobacco smoke, and how tissue-resident lymphocytes can...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $602,955 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to National Jewish Health in Denver, Colorado. The 5-year grant, running from July 2024 to June 2029, will fund research to identify the unique functions and molecular drivers of airspace macrophage subsets during the resolution of lung inflammation and active lung repair. The primary objectives are to: 1) Test the hypothesis that a subset of airspace...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $277,610 to Duke University to determine the role of TP53 regulation in alveolar epithelial transitional cell state, and the contribution of alveolar epithelial transitional cell state to pulmonary fibrosis. The project aims to uncover the molecular mechanisms that regulate alveolar epithelial cell states and understand the impact...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $773,446 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Washington University to conduct research on the spatiotemporal control of early matricellular events in the injured lung. The research aims to better understand how the matricellular protein thrombospondin-1 (TSP1) regulates the formation and stabilization of the provisional extracellular matrix during acute lung injury, with the goal...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a 4-year, $721,826 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant funds research to identify molecular mechanisms regulating the function of alveolar matrix fibroblasts and their role in supporting vascular network formation during postnatal lung development. The research aims to elucidate the transcriptional regulator MEOX2 and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding research at Northwestern University to investigate the role of mitochondrial metabolism in alveolar epithelial cell differentiation and the development of lung fibrosis. The $616,000 award, effective September 1, 2024 through August 31, 2029, will support experiments using genetic mouse models to determine how mitochondrial...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $545,400 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Georgia Tech Research Corp to elucidate the role of focal adhesion kinase (FAK) mechanosensing in extracellular matrix remodeling, senescence, and apoptosis-resistance in pulmonary fibrosis. The project will utilize a 3D bioengineered microtissue model to study these mechanisms in normal and senescent fibroblasts, and evaluate the...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $740,317 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The Washington University in St. Louis to study the regulation of primary and secondary alveologenesis by FGF signaling pathways. The research aims to identify the cellular mechanisms by which FGF signaling regulates cell proliferation, differentiation, and death during the first and second stages of alveolar development. This work could provide insights into...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,061,189 to the Regents of the University of Michigan to conduct research on the mechanisms underlying lung injury, fibrosis, and susceptibility to bacterial infections. The key objectives are to study: 1) how epithelial cell signaling regulates fibrosis and interacts with myeloid cells, 2) the impaired innate immunity against...
The U.S. National Heart, Lung, and Blood Institute (NHLBI) awarded a $798,727 Cooperative Agreement under the Cardiovascular Diseases Research program (CFDA 93.837) to The Trustees of the University of Pennsylvania (University of Pennsylvania) for the "The Penn LungMAP 3 Team: Defining Chronic Lung Disease" project. This 5-year effort aims to expand understanding of human lung diseases, with a focus on cataloging cellular and molecular changes in chronic lung diseases like COPD and...